ROBO Global Healthcare Technology and Innovation ETF (HTEC) seeks to track the ROBO Global Healthcare Technology and Innovation Index, which measures companies developing transformative technologies in healthcare including robotics, artificial intelligence, telemedicine, and biotechnology innovations. This specialized equity ETF provides global exposure to healthcare technology disruptors.
How It Works
HTEC uses a rules-based, modified market-capitalization-weighted approach that screens companies based on their involvement in healthcare technology innovation. The underlying index selects firms generating significant revenue from healthcare robotics, AI diagnostics, digital health platforms, and medical device automation. Holdings are weighted by market cap with position limits to prevent over-concentration. Rebalancing occurs semi-annually to capture emerging healthcare technology leaders and maintain sector diversification across developed and emerging markets.
Key Features
- Targets pure-play healthcare technology companies rather than broad healthcare or general technology ETFs
- Global diversification includes emerging market healthcare innovators often missed by U.S.-focused technology funds
- Rules-based screening identifies companies with substantial healthcare technology revenue, not just peripheral exposure
Risks
- This ETF can lose significant value during technology sector selloffs, as healthcare tech stocks often trade at high valuations vulnerable to multiple compression
- Concentration in emerging healthcare technologies means many holdings may be unprofitable, creating higher volatility than established healthcare companies
- Global exposure adds currency risk and regulatory uncertainty, particularly for companies operating across different healthcare regulatory environments
Who Should Own This
Best suited as a satellite holding (5-15% of portfolio) for growth-oriented investors with 7+ year time horizons and high risk tolerance. Appropriate for those seeking targeted exposure to healthcare innovation trends beyond traditional pharmaceutical companies. Works well for thematic investors building technology-focused portfolios or healthcare sector allocations.